Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development-Reference-Cited by-同舟云学术

Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development

Published:2023-01-17 Issue: Volume: Page:
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Coutant David E.¹^ORCID,Boulton David W.²,Dahal Upendra P.³,Deslandes Antoine⁴,Grimaldi Christine⁵,Pereira Joao N.S.⁶,Säll Carolina⁷,Sarvaiya Hetal⁸,Schiller Hilmar⁹^ORCID,Tai Guoying¹⁰,Umehara Kenichi¹¹,Yuan Yang¹²,Dallas Shannon¹³

Affiliation:

1. Drug Disposition Department Eli Lilly and Company Indianapolis Indiana USA

2. Clinical Pharmacology and Quantitative Pharmacology Clinical Pharmacology and Safety Sciences, Research & Development, AstraZeneca Gaithersburg Maryland USA

3. Pharmacokinetics and Drug Metabolism Amgen, Inc. South San Francisco California USA

4. Translational Medicine and Early Development Sanofi Research & Development Chilly‐Mazarin France

5. Formerly of Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc Ridgefield Connecticut USA

6. Drug Disposition & Design Merck Healthcare KGaA Darmstadt Germany

7. Development Absorption, Distribution, Metabolism, and Elimination Novo Nordisk A/S Måløv Denmark

8. Drug Metabolism, Pharmacokinetics, and Bioanalytical, AbbVie Inc. California South San Francisco USA

9. Pharmacokinetic Sciences Novartis Institutes for BioMedical Research Basel Switzerland

10. Department of Metabolism and Pharmacokinetics GlaxoSmithKline Collegeville Pennsylvania USA

11. Pharmaceutical Sciences Roche Pharma Research & Early Development, Roche Innovation Center Basel Basel Switzerland

12. Formerly of Department of Metabolism and Pharmacokinetics Bristol Myers Squibb Pharmaceutical Research and Development Princeton New Jersey USA

13. Preclinical Sciences & Translational Safety Janssen Research & Development Springhouse Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2814

Reference75 articles.

1. US Food and Drug Administration.Draft guidance: drug–drug interaction assessment for therapeutic proteins. (2020). Accessed February 10 2022.

2. Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

3. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab

4. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

5. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab;CPT: Pharmacometrics & Systems Pharmacology;2024-06-03

2. Exposure of cinnamyl alcohol in co‐culture of BEAS‐2B and dendritic cells: Interaction between CYP450 and cytokines;Journal of Applied Toxicology;2024-05-07

3. Probing the interaction behavior of Nano-Resveratrol with α-lactalbumin in the presence of β-lactoglobulin and β-casein: spectroscopy and molecular simulation studies;Journal of Biomolecular Structure and Dynamics;2024-02-12

4. Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling;CPT: Pharmacometrics & Systems Pharmacology;2023-12-04

5. Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4‐Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach;Clinical Pharmacology & Therapeutics;2023-12-03